Glycihal 1GV Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in a reduction of postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting better compliance and minimizing gastrointestinal side effects commonly associated with immediate-release preparations. Glycihal 1GV is indicated for patients inadequately controlled by diet, exercise, and monotherapy, providing a multifaceted approach to glycemic management by targeting different pathophysiological defects of type 2 diabetes. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis or severe metabolic acidosis. This combination therapy should be used under medical supervision to optimize efficacy and minimize adverse effects.